2023 World Conference on Lung Cancer (Posters)-EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients

EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the outcomes of small cell lung cancer (SCLC) patients based on real-world data and clinical trial data. The researchers generated a mixed cohort that included SCLC patients who had received platinum-based chemotherapy. The retrospective real-world data was obtained from Karolinska University Hospital, while the comparative group included participants from three randomized phase III clinical trials. The overall survival of the patients was analyzed using Cox hazard ratios, and the included covariates were age, sex, brain metastasis, ECOG performance status, and the source of the data.<br /><br />The study cohort had a median overall survival of 8 months, and hazard ratios for sex and performance status were statistically significant. The real-world data provided a worse prognosis compared to the clinical trials, particularly for one of the trials with a high rate of censoring. After removing censored patients, the hazard ratios of the three studies were not statistically significant except for the trial with the high censoring rate.<br /><br />Based on the findings, the outcomes between two of the three randomized clinical trials were similar to those of the real-world dataset. This suggests that real-world data could potentially be used to inform decision-making for SCLC patients. The analysis highlighted the differences in outcomes between real-world data and clinical trials, which may be attributed to the different operations and patient exclusions in these settings.<br /><br />In summary, this study demonstrated the potential utility of real-world data in evaluating outcomes for SCLC patients. The analysis revealed differences in outcomes between real-world data and clinical trials, emphasizing the importance of considering real-world evidence in clinical practice and trial design for SCLC.

Asset Subtitle

Luca Marzano

Meta Tag

Speaker Luca Marzano

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

small cell lung cancer

real-world data

clinical trial data

platinum-based chemotherapy

retrospective

overall survival

Cox hazard ratios

prognosis

censoring

real-world evidence